- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00631228
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study (XIENCE V India)
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study
연구 개요
상세 설명
Long term surveillance studies using a drug eluting stent (DES) may help elucidate mechanisms responsible for death, myocardial infarction, and late stent thrombosis risks not observed during controlled pre-market trials. This study will evaluate XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) performance in the "real world" when used by a broad group of physicians at a variety of health care facilities. Consequently, this protocol will include all consecutively enrolled patients in India who consent to participate and receive the XIENCE V® EECSS, which is expected to represent the range of clinical use during commercialization.
Adjunctive anti-platelet therapy is a critical factor in optimizing long term DES safety. Despite established guidelines that recommend 6-12 months dual antiplatelet therapy, patients with DES implants frequently stop taking their medication early. Consequently, XIENCE V® EECSS India Post-marketing Single-Arm Study (XIENCE V® India) follow-up will document patient adherence and persistence with adjunctive antiplatelet drug therapy at several time points throughout the study.
The long term safety and efficacy of the XIENCE V EECSS have been demonstrated in the SPIRIT FIRST trial up to 5 years, the SPIRIT II trial up to 4 years, and in the SPIRIT III Randomized Control Trial (RCT) up to 3 years. In addition, these pre-approval studies have shown low rates of Target Vessel Failure and Major Adverse Cardiac Events (MACE) that were observed to plateau or gradually decline after about 1 year and were consistently lower than the comparator arm of each study. This benefit in MACE is sustained for up to 5 years and is also independent of the first year results.
The post approval XIENCE V India study demonstrated that the use of the XIENCE EECSS in complex lesions in a real-world population resulted in 1 year MACE, Stent Thrombosis and Target Lesion Revascularization rates that are comparable to those of the previously mentioned pre-approval studies which included patients with more restricted inclusion / exclusion criteria.
Therefore, based on existing data from these trials, Abbott Vascular has decided to discontinue further follow up in the XIENCE V India study, from 5 years to after completion of the three year follow-up.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Ahmedabad, 인도, 380054
- Sal Hospital and Medical Institute
-
Amritsar, 인도
- Escorts Heart & Superspeciality Institute Ltd.
-
Chennai, 인도, 600 037
- Madras Medical Mission
-
Cochin, 인도
- Lisie Heart Institute,Lisie Hosp.
-
Hyderabad, 인도, 500033
- Apollo Hospital
-
Jaipur, 인도
- Heart & General Hospital
-
Mumbai, 인도, 400050
- Holy Family Hospital
-
New Delhi, 인도, 110025
- Escorts Heart Institute & Research Centre
-
New Delhi, 인도, 110017
- Max Devki Devi Heart & Vascular Institute
-
New Delhi, 인도, 110 070
- Escorts Heart Institute & Research Centre
-
New Delhi, 인도, 110 070
- Fortis Hospital
-
Pune, 인도, 411030
- Poona hospital and research centre
-
Pune, 인도, 411001
- Jehangir Hospital
-
-
Andhra Pradesh
-
Hyderabaad, Andhra Pradesh, 인도, 500034
- Care Hospital
-
Hyderabad, Andhra Pradesh, 인도, 5000003
- Krishna Heart Institute,
-
-
Gujarat
-
Ahmedabad, Gujarat, 인도, 380 006
- Krishna Heart Institute
-
-
Punjab
-
Ludhiana, Punjab, 인도, 141001
- Dayanand Medical College & Hospital
-
-
Tamilnadu
-
Vellore, Tamilnadu, 인도, 632004
- Christian Medical Center (CMC)
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- The patient agrees to participate in this study by signing the EC approved informed consent form. Alternatively, the patient's legally authorized representative agrees to the patient's participation in this study and signs the informed consent form.
Exclusion Criteria:
- The inability to obtain an informed consent is an exclusion criterion.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
1
The group will be monitored to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
|
Drug eluting stent implantation stent in the treatment of coronary artery disease
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Stent thrombosis rates as defined by Academic Research Consortium (ARC)
기간: Annually through to 3 years
|
Annually through to 3 years
|
Composite endpoint of cardiac death and myocardial infarction (MI)
기간: at 1 year
|
at 1 year
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Composite rate of cardiac death and any MI (Q-wave and non Q-wave)
기간: at 30, 180 days and at 2 and 3 years
|
at 30, 180 days and at 2 and 3 years
|
Composite rate of all death and any MI (Q-wave and non Q-wave)
기간: at 30, 180 days and at 2 and 3 years
|
at 30, 180 days and at 2 and 3 years
|
Composite rate of cardiac death , any MI (Q-wave and non Q-wave) attributed to the target vessel, and target lesion revascularization (PCI and CABG)
기간: at 30, 180 days and at 2 and 3 years
|
at 30, 180 days and at 2 and 3 years
|
Death (cardiac death, vascular death, and non-cardiovascular death)
기간: at 30, 180 days and at 2 and 3 years
|
at 30, 180 days and at 2 and 3 years
|
Any MI (Q-wave and non Q-wave)
기간: at 30, 180 days and at 2 and 3 years
|
at 30, 180 days and at 2 and 3 years
|
Major bleeding complications
기간: at 14, 30, 180 days and at 1, 2 and 3 years
|
at 14, 30, 180 days and at 1, 2 and 3 years
|
Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy
기간: at 14, 30, 180 days and at 1, 2 and 3 years
|
at 14, 30, 180 days and at 1, 2 and 3 years
|
Revascularization (target lesion, target vessel [TVR], and non-target vessel) (PCI and CABG)
기간: at 30, 180 days and at 1, 2 and 3 years
|
at 30, 180 days and at 1, 2 and 3 years
|
Clinical device and procedural success
기간: Acute
|
Acute
|
Patient health status (symptoms, physical function, and quality of life) assessed by the Seattle Angina Questionnaire
기간: at baseline, 180 days, and 1 year
|
at baseline, 180 days, and 1 year
|
Stent thrombosis
기간: 24 hours (acute) and 30 days (sub-acute)
|
24 hours (acute) and 30 days (sub-acute)
|
Composite rate of all death, any MI (Q-wave and non Q-wave) and any repeat revascularization (PCI and CABG)
기간: 30, 180 days and 1, 2 and 3 years
|
30, 180 days and 1, 2 and 3 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Ashok Seth, MD, Max Devki Devi Heart & Vascular Institute
- 수석 연구원: Tejas Patel, MD, Krishna Heart Institute
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 07-378
- REFCTRI000213, 21-10-2008 (레지스트리 식별자: Clinical Trials Registry - India)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
관상동맥 질환에 대한 임상 시험
-
Chinese Academy of Medical Sciences, Fuwai HospitalMedtronic; CCRF Consulting Co., Ltd.빼는Transradial-transfemoral Coronary Interventions 비교
-
CCRF Consulting Co., Ltd.Peking University First Hospital; Terumo Medical(shanghai) Co.,Ltd.알려지지 않은심장 또는 뇌혈관 질환 무료 요금 | Transradial-transfemoral Coronary Interventions 비교중국
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
Micell TechnologiesCardialysis BV; ClinLogix. LLC알려지지 않은
-
University Medical Center Groningen모병
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); US Department...완전한신장 질환 | 만성 신장 질환 | 급성 신부전 | 관상동맥(Artery); 질병
XIENCE V® Everolimus Eluting Coronary Stent에 대한 임상 시험
-
Abbott Medical Devices완전한심근 허혈 | 관상동맥 질환 | 관상 동맥 질환 | 스텐트 혈전증 | 관상동맥 재협착 | 만성 관상 동맥 폐색 | 혈관 질환 | 관상 동맥 협착증 | 혈관 성형술미국
-
Abbott Medical Devices완전한심근 경색증 | 관상동맥 질환 | 심혈관 질환 | 관상 동맥 심장 질환 | 스텐트 혈전증 | 관상동맥 재협착 | 혈관 질환 | 혈관 성형술미국
-
Spanish Society of Cardiology알려지지 않은
-
Concept Medical Inc.모집하지 않고 적극적으로관상동맥 질환 | 당뇨병 | 급성관상동맥증후군스위스, 호주, 대한민국, 프랑스, 벨기에, 네덜란드, 영국, 인도, 오스트리아, 방글라데시, 브라질, 체코, 독일, 아일랜드, 이탈리아, 말레이시아, 멕시코, 폴란드, 싱가포르, 스웨덴, 대만
-
Sydney South West Area Health Service알려지지 않은
-
Abbott Medical Devices모집하지 않고 적극적으로
-
Abbott Medical Devices완전한관상동맥 질환 | 관상 동맥 질환 | 관상동맥 재협착아일랜드, 네덜란드, 싱가포르, 스페인, 중국, 벨기에, 스위스, 태국, 이스라엘, 독일, 뉴질랜드, 영국, 이탈리아, 말레이시아, 캐나다, 인도, 오스트리아, 프랑스, 남아프리카, 포르투갈, 체코 공화국, 그리스, 스웨덴
-
Abbott Medical Devices완전한심근 허혈 | 관상동맥 질환 | 스텐트 혈전증 | 혈관 질환 | 관상 동맥 협착증 | 스텐트 | 전체 관상 동맥 폐색 | 관상동맥 재협착증미국
-
Abbott Medical Devices완전한관상동맥 질환 | 관상 동맥 질환 | 관상동맥 재협착네덜란드, 스페인, 덴마크, 독일, 프랑스, 오스트리아, 벨기에, 인도, 이탈리아, 뉴질랜드, 폴란드, 남아프리카, 스위스